





# **Biotechnology and Pharmaceuticals**

in the Capital Region Berlin-Brandenburg

### THE GERMAN CAPITAL REGION

excellence in life sciences & healthcare



Takeda's Oranienburg location – center of excellence for fixed forms in the worldwide production network



The CoLaborator from Bayer provides the perfect environment for young companies in the life sciences.

#### Biotech

Analyticon Discovery Biochrom **BIOTECON Diagnostics** Co.don Epigenomics Glycotope Ifp Institut für Produktgualität In.vent DIAGNOSTICA InVivo Biotech Services JPT Peptide Technologies **KNAUER** Wissenschaftliche Geräte LGC metanomics MOLOGEN **NOXXON** Pharma ProBioGen Seramun Diagnostica SGS INSTITUT **FRESENIUS Berlin** SIFIN Silence Therapeutics Thermo Fisher Scientific -**B**·R·A·H·M·S **TIB MOLBIOL** 

For a complete overview of all the companies, see www.healthcapital.de

## Leading European location for biotechnology

Biotechnology is an engine of innovation in the Berlin-Brandenburg region. The sector is recording steady growth and a high rate of company start-ups. This positive trend is based on the region's excellent research landscape and technology parks specialized in biotechnology. They provide optimal conditions for start-ups and large, research-intensive companies alike. Of the more than 230 biotechnology companies with approx. 4,600 employees here, 80% focus on biomedicine. They develop innovative therapeutic and diagnostic procedures for the treatment of cancer, cardiovascular diseases and diabetes, and benefit from the region's excellent science and top infrastructure for clinical studies. Berlin-Brandenburg possesses expertise in genome and proteome research, diagnostics, regenerative medicine, RNA technologies and glyco-engineering technology.



»We have made a conscious decision to locate our business in Berlin. This booming city offers innovative companies like SPMSD and its employees a highly attractive, inspiring environment. We are a pharmaceuticals company, and moving from our traditional location

to a new one is not something we do every day. This is why the support we received for our location and funding search and employee relocation was very helpful.«

Dr. Oliver Sadlek Vice President, General Manager, Germany and Austria Sanofi Pasteur MSD GmbH



»The outstanding network is a major advantage of the capital region. In the field of diagnostics in particular, the exchange and partnerships between companies and the excellent research institutions is optimally supported here.«

Dr. Tim Bölke CEO Metanomics Health GmbH

### Pharmaceuticals location with a rich history and modern dynamics

The sustained success of pharmaceuticals companies in Berlin and Brandenburg is based on innovative products and a venerable tradition reaching back to the 19th century. The sector benefits from an excellent scientific environment and clinical research landscape, and its proximity to the health care system decision makers. This applies to global players such as Bayer, Pfizer, Sanofi, Takeda and Berlin-Chemie (Menarini) and to more than 20 additional medium-sized pharmaceuticals companies with a total of 10,000 employees. Many international corporations such as Daiichi Sankyo and Astra Zeneca also have representative offices in Berlin.

Bayer HealthCare Pharmaceuticals can look back at a long history in Berlin. Today, the company is one of the world's 10 largest speciality pharmaceuticals companies. More than 1,000 Sanofi employees manage the company's marketing and sales activities in Berlin. In 2011, Takeda Pharma took over the Nycomed Group and only one year later, moved its sales headquarters to Berlin. Takeda is currently investing €100 million to expand its production facilities in Oranienburg. Pharmaceuticals giant Pfizer is also expanding its activities in the



Production of biomarkers at B.R.A.H.M.S GmbH in Hennigsdorf

- Leading German biotechnology location with over 230 companies in the sector
- Pharmaceuticals location with a rich history
- Outstanding conditions for clinical research
- Excellent access to skilled specialists due to the many degree, training and continuing education programs
- Outstanding science landscape featuring Charité Universitätsmedizin Berlin and many other university and non-university research institutions (Max Planck, Fraunhofer and Leibniz Institutes and the Helmholtz Centers)
- Political center and seat of the vfa, BPI and BIO Deutschland sector associations, as well as health insurance companies and patient organisations
- Tight network among science and business through interdisciplinary partnerships in the areas of biotechnology, diagnostics, pharmaceuticals, medical technology, photonics and ICT, as well as partnerships as part of sector networks

capital region, establishing other business units to supplement its German headquarters here. For example, the company manages its oncology business unit for Europe from Berlin. In 2014, the French-American joint venture Sanofi Pasteur MSD decided to move its German headquarters to Berlin - as did Riemser Pharma, which is reinforcing its sales activities with an operations-related unit in Berlin. Berlin-Chemie is investing €80 million to expand its production facilities in the south of Berlin. Dr. Kade, which has been growing in the capital region for over 25 years, has taken over Takeda's OTC business. And the fact that Klosterfrau Berlin invested in a new production hall in 2013 also shows that Berlin has developed into an important production location in recent years.

#### **Clinical research**

The close connection between research, development and the clinics here is most obviously demonstrated by the region's successful, well-established translational research and the wide range of opportunities available for implementing clinical studies. With its large, extremely diverse patient collective, Berlin-



»Since we were spun off from Freie Universität Berlin in 1998, we have been located on the Campus. We benefit from our proximity to the research institutions there, and the capital region is highly attractive to qualified employees – especially to our international employees.«

Dr. Matthias Schroff CEO MOLOGEN AG



»Between its market organization in Berlin-Mitte and production in Oranienburg, Takeda employs over 800 people in the capital region. The company trains them and is constantly generating new jobs. As an innovative pharmaceuticals company, we concentrate on special prescription drugs for medical specialists.«

Jean-Luc Delay CEO Takeda Pharma Vertrieb GmbH & Co. KG

Brandenburg facilitates all kinds of clinical research projects. Charité – Universitätsmedizin Berlin and CROs such as Parexel – active with over 1,000 employees in Berlin – and other smaller providers that supervise studies of all types all play outstanding roles in this area.

#### **Optimal conditions for start-ups**

The seven biotechnology parks in the region provide optimal conditions for young, growing companies. Over 50% of the biotechnology companies use the programs of the stateowned or privately operated parks, which offer a variety of contextual focal areas. In addition to the availability of laboratory space and an extensive technical infrastructure, they benefit from the close contact and intense exchange with the research institutions and multi-faceted service providers that are also located in the parks.

When it comes to early stage financing, the states' own business development banks have investment companies whose technology funds play an important role. Projects such as Bayer's CoLaborator are evidence of the major pharmaceuticals corporations' involvement.

Pharma Aenova/ Haupt Pharma Berlin Aristo Pharma Bausch + Lomb Bayer HealthCare Pharmaceuticals Berlin-Chemie (Menarini Group) DR KADF Pharmazeutische Fabrik Klosterfrau Berlin Merz Pharmaceuticals Pfizer Riemser Pharma Sanofi Sanofi Pasteur MSD Shire Takeda Pharma Teva

#### Networks

BioResponse Network Center for Molecular Diagnostics and Bioanalytics (ZMDB) DiagnostikNet-BB Regenerative Medicine Initiative Berlin-Brandenburg (RMIB) RiNA-Network RNA-Technologies

#### Biotech-Parks

berlinbiotechpark Biotech Campus Potsdam Biotechnologiepark Luckenwalde Campus Berlin-Buch co:bios Technologiezentrum Hennigsdorf GO:IN Golm Innovationszentrum, Potsdam Science and Technology Park Adlershof



### Our aim: your success!

Berlin and Brandenburg support the biotechnology and pharma focal area with an economic policy developed across state borders in the Healthcare industries cluster. The cluster is managed under the aegis of Berlin Partner for Business and Technology and ZAB ZukunftsAgentur Brandenburg.

Our aim is to provide comprehensive support to companies and scientific institutions interested in inward investment or further development in the capital region.

We are ready to assist you with:

- Company start-up
- Location search
- Funding and financing
- Technology transfer and R&D partnerships
- Cooperating in networks

Reach out and contact us! www.healthcapital.de

- Employee recruiting, programs designed to retain skilled specialists and qualification
- International market development

PHOTOS: Cover: YAZ-Flex production in Berlin, Bayer. Inside: Takeda/Sebastian Bolesch, Bayer, B•R•A•H•M•S DESIGN: Büro Watkinson, Berlin. PRINT: LASERLINE, Berlin

© December 2014



Berlin Partner für Wirtschaft und Technologie GmbH Fasanenstraße 85 10623 Berlin www.berlin-partner.de Twitter: @BerlinPartner

Contact: Carolin Clement Tel +49 30 46302 430 carolin.clement@berlin-partner.de



ZAB ZukunftsAgentur Brandenburg GmbH Steinstraße 104-106 14480 Potsdam www.zab-brandenburg.de

Contact: Stefan Bauer Tel +49 331 20029 253 stefan.bauer@zab-brandenburg.de

#### Investing in your future!



Publisher: Berlin Partner for Business and Technology in cooperation with ZAB Brandenburg Economic Development Board, commissioned by the Berlin State Senate Department for Economics, Technology and Research and the Brandenburg State Ministry for Economic Affairs and Energy. Funded by the State of Berlin and the State of Brandenburg as well as the Investitionsbank Berlin, cofunded by the European Union – European Regional Development Fund.